Advice

in the absence of a submission from the holder of the marketing authorisation:

crizotinib (Xalkori®) is not recommended for use within NHSScotland.

Indication under review: as monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with:

  • relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL)

  • recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

 

Download detailed advice621KB (PDF)

Download

Medicine details

Medicine name:
crizotinib (Xalkori)
SMC ID:
SMC2621
Indication:

As monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with:

  • relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL)
  • recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT)
Pharmaceutical company
Pfizer Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
11 September 2023